Compare Novavax Inc (NVAX) vs Roblox Corp (RBLX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Novavax Inc vs Roblox Corp — how do they compare? Novavax Inc trades at $9.88 (market cap $1.68B), while Roblox Corp trades at $44.53 (market cap $32.02B). The key difference: Roblox Corp is far larger — about 19.1× Novavax Inc's market cap, and Novavax Inc is trading nearer its 52-week high, Roblox Corp nearer its low. Which is the better fit depends on your goals.
| NVAX | RBLX | |
|---|---|---|
Market Cap | $1.68B | $32.02B |
Sector | Health | Media |
52-Week High | $11.19 | $141.56 |
52-Week Low | $6.22 | $35.54 |
Enterprise Value | $1.26B | $30.84B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Novavax (NVAX) trades at $10.19, showing modest daily movement with a -0.29% decline. The stock maintains a bullish technical signal with strong moving average support. Recent quarterly earnings have consistently beaten expectations, though the company faces profitability challenges with a -59.87% net income margin. Positive developments include regulatory approvals for its updated COVID-19 vaccine and progress in the Sanofi partnership, driving investor optimism.
The outlook remains mixed with strong analyst support (74% buy ratings) but significant financial risks. Investment opportunity lies in the company's partnership strategy and Matrix-M adjuvant platform, while risks include cash flow challenges and competitive vaccine market pressures. The stock's low P/E ratio of 3.14 suggests potential undervaluation if operational improvements continue.
RBLX trades at $44.82, up 3.49% today, near the consensus price target of $45.71. The stock shows bullish technical signals with strong support at $43 and resistance at $46. Revenue growth is robust, rising to $4.89B in 2025, but net losses persist at -$1.07B. Recent news highlights regulatory scrutiny in the EU and Australia over child safety, alongside positive economic impact from creator earnings.
Outlook remains mixed: strong revenue growth and cash flow improvement support long-term potential, but profitability challenges and regulatory risks weigh on sentiment. Analysts are divided, with 44.7% recommending buy. The key catalyst is achieving sustained profitability amid expanding user engagement.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Novavax Inc
Novavax, Inc. is a clinical stage biotechnology company. The Company creates novel vaccines to address a broad range of infectious diseases worldwide using proprietary virus-like particle (VLP) technology.
Read more on NVAX →About Roblox Corp
Roblox operates an online video game platform that lets young gamers create, develop, and monetize games (or experiences) for other players. The firm effectively offers its developers a hybrid of a game engine, publishing platform, online hosting and services, marketplace with payment processing, and social network. The platform is a closed garden that Roblox controls, earning revenue in multiple places while benefiting from outsourced game development. Unlike traditional video game publishers, Roblox is more focused on the creation of new tools and monetization techniques for its developers then creating new games or franchises. Roblox is increasingly focused on creating a metaverse that moves beyond games toward experiences like concerts, education, and even business management.
Read more on RBLX →
